NKGen Biotech

Closed (deSPAC)

Profile in progress

What it is: Biotech, Inc
What it’s doing now: Merging with Graf Acquisition Corp. IV (GFOR) — closed (despac).
What you should know: The deal carries a $50M minimum-cash condition — heavy redemptions can break it.

The business, per its filings

SEC primary

Biotech, Inc. NKGen Biotech, Inc. is a clinical-stage biotechnology company incorporated as a Delaware corporation and focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. The company is headquartered in Santa Ana, CA.

What the company says about itself

Web research — not audited

NKGen Biotech is leveraging the power of a patient’s immune system through the development of unique natural killer (NK) cell therapies. Their technology, NKMax, aims to restore immune function and enhance a patient’s ability to target and eliminate diseased cells.

Markets:: Biotechnology | Immunotherapy
Products:: NKMax | SNK Cell Therapy

What our web check found

[WEB-INTEL 2026-08-26] 4 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "$39,922,134.22 secured convertible loan at 12% interest, adds a $0.08 conversion note, warrant, 11807380 shares" [https://www.stocktitan.net/sec-filings/NKGN/8-k-nk-gen-biotech-inc-reports-material-event-1eadec7e170d.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "NKGen Biotech obtains a $39922134.22 secured convertible loan at 12% interest, adds a $0.08 conversion note, warrant, 11807380 shares" [https://www.stocktitan.net/sec-filings/NKGN/8-k-nk-gen-biotech-inc-reports-material-event-1eadec7e170d.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "AlpineBrook provided the majority of the $17 million funding to NKGen for the purchase of NKMax shares." [https://www.otcmarkets.com/filing/html?id=18764290&guid=hqE-kWlPRueEdth] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "In October 2023, NKGen made the pivotal decision to go public in the U.S., securing a $25 million backstop commitment from NKMax to fund ..." [https://firstwordpharma.com/story/6058405]

Source: https://nkgenbiotech.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

NKGen Biotech is merging with Graf Acquisition Corp. IV (GFOR) currently marked Closed (deSPAC).

Headline equity value	—
Minimum cash to close	$50M

Structure per SEC accession(s) 0001104659-23-060652. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is NKGen Biotech going public?

NKGen Biotech has an approved merger with the SPAC Graf Acquisition Corp. IV (GFOR). Deal status: Closed (deSPAC).

Does NKGen Biotech have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.